 |
|
Very Late Antigen 1 Blockade Markedly Promotes Survival of Corneal Allografts
Lu Chen, MD, PhD;
Syed Huq, MD;
Humphrey Gardner, MD;
Antonin R. de Fougerolles, PhD;
Stefano Barabino, MD;
M. Reza Dana, MD, MSc, MPH
Arch Ophthalmol. 2007;125(6):783-788.
Objective To investigate the role of very late antigen 1 (VLA-1) (also known as integrin receptor  1β1) in corneal transplantation inflammation and allograft survival.
Methods Cell infiltration and vasculogenesis (both angiogenesis and lymphangiogenesis) associated with allodisparate corneal transplantation were assessed in VLA-1–deficient conditions and controls by immunofluorescent microscopic studies. Corneal allograft survival was also assessed after anti–VLA-1 antibody treatment and in VLA-1 knockout recipient mice.
Results Anti–VLA-1 antibody treatment leads to a profound reduction in the granulocytic, monocytic, and T-cell infiltration after corneal transplantation. In addition, corneal angiogenesis and lymphangiogenesis were both significantly suppressed in VLA-1 knockout mice. Remarkably, universal graft survival was observed in both anti–VLA-1 antibody treatment and knockout mice.
Conclusions Very late antigen 1 blockade markedly reduces inflammation and inflammation-induced tissue responses, including vasculogenic responses, associated with corneal transplantation and promotes allograft survival.
Clinical Relevance These studies offer insights into important integrin-mediated mechanisms of corneal transplant–related inflammation and provide possible new integrin-based immunotherapies for transplant rejection.
Author Affiliations: Laboratory of Immunology, Schepens Eye Research Institute and Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School, Boston, Mass (Drs Chen, Huq, Barabino, and Dana); Research Pathology, Biogen Idec (Drs Gardner and de Fougerolles), Cambridge, Mass.
|
